Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Frank Zhang

Legend Biotech Corporation

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Metric
Company Name	Legend Biotech Corporation	LégiaPark	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	LEGN
MSH ID	COM:LEGENDBIOTECH	BE:LEGIAPARK	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences	Pharmaceuticals
Country	US	BE	US
Stage			Series B
Employee Count	2K
Website	legendbiotech.com	legiapark.be	xynomicpharma.com
LinkedIn		l%C3%A9giapark
Founders

Metric
Market Cap	8.63B
Enterprise Value
Monthly Web Traffic		1.52K
Web Traffic Growth		4.19
Valuation
Raised Capital

Metric
Revenue	285.14M
Revenue (LTM)
Revenue (NTM)
Gross Profit	140.93M
EBITDA	-442.22M
Operating Income	-442.22M
Net Income	-518.25M
EPS	-2.94
Diluted EPS	-2.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.57
Operating Profit Margin	-0.76
EBITDA Margin	-1.55
Net Profit Margin	-0.63
Return on Equity	-0.23
Return on Assets	-0.16
Return on Capital Employed	-0.23

COM:LEGENDBIOTECH

Legend Biotech

Last Close

36.39

14/02 21:00

Market Cap

8.63B

Beta: -

Volume Today

785.46K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-39.80
P/B Ratio	15.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	36.63
EV Multiple	-20.52

Metric
Days Sales Outstanding	77.73
Days Payables Outstanding	46.52
Days Inventory Outstanding	47.42
Operating Cycle	248.47
Cash Conversion Cycle	199.27
Asset Turnover	0.25

Metric
Operating Cash Flow	-384.47M
Free Cash Flow	-505.97M
Cash Flow to Debt	-0.47
Operating Cash Flow/Sales	-0.30
Free Cash Flow Yield	-0.03

Metric
Cash & Equivalents	1.28B
Accounts Receivable	-98.98M
Inventory	19.43M
Goodwill
Debt to Capitalization	0.20
Debt to Assets	0.17
Current Ratio	8.61
Quick Ratio	6.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09
R&D to Revenue	1.53
SG&A to Revenue	0.45